#Cannabis Stock News: Hydropothecary Corporation (TSX VENTURE: THCX) set to release Canada's first-ever medical cannabis mouth spray
GATINEAU, QC - July 25, 2017 (Investorideas.com Newswire) The Hydropothecary Corporation (TSX VENTURE: THCX) today announced it will soon launch Elixir No. 1 Canada's only legal medical marijuana sublingual (under tongue) mist.
This new product, in a natural peppermint oil base and is approved for production and sale under the ACMPR by Health Canada, will begin shipping on July 31, 2017.
Packaged in a child-resistant, 15ml spray bottle, Elixir No. 1 is a smoke-free, ready to use, high THC product. It contains close to the maximum allowable THC level of 30mg/ml for a cannabis oil under current Health Canada regulations.
The mist can be sprayed directly under the tongue or mixed with food or drinks, and provides a discreet, convenient and ready to use alternative to dried medical marijuana products.
"With the introduction of Elixir No. 1, Hydropothecary is answering the needs of any Canadian looking for smoke-free and ready to consume alternatives. Our easy to use, easy to understand products, including our line of Decarb products and capsules, are part of Hydropothecary's commitment to innovative product development. As a result, we expect demand for Elixir No. 1 to be strong from the outset," said Sebastien St-Louis, CEO and co-founder.
Elixir No. 1 will be available from the Hydropothecary online store for $89 a bottle.
For more information on Elixir No.1, please visit www.thehydropothecary.com/products
For images, please click here: www.thc.vc/ElixirMedia *please note that the URL is case sensitive
About The Hydropothecary Corporation
The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides naturally grown and rigorously tested medical cannabis of uncompromising quality. Hydropothecary's branding, cannabis product offering, patient service standards and product pricing are consistent with THCX's positioning as a premium brand for a legal source for medical cannabis within this new marketplace. In addition to medical cannabis production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical cannabis, as well as the import and export of medical cannabis.
For media inquiries please contact:
For investor relations:
For contact information:
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.